Table 2. SCID mouse experiments with simvastatin.

LCL	Group	No. of cells	No. of mice*	Time of therapy†	Simvastatin days (mg/kg/day)	50% survival, days	Day of death, range in days			p (logrank)‡
12A1	1	0.25 × 106	6	Pretreatment	−3 to +28 (250)	81	70 to >105	]		0.0496
	2	0.25 × 106	10	No treatment	−(0)	56	45-105
	3	1 × 106	6	Pretreatment	−3 to +28 (250)	56	53 to >105	]		0.0350
	4	1 × 106	12	No treatment	−(0)	53	48-56
	5	4 × 106	10	Pretreatment	−3 to +28 (250)	56	49-57	]		<0.0001
	6	4 × 106	12	No treatment	−(0)	46	43-50
6B10	7	1 × 106	10	Pretreatment	−3 to +44 (250)	>100	64 to >100	]		0.0375
	8	1 × 106	11	Treatment	+7 to +44 (250)	85	76 to >100		]	0.2135
	9	1 × 106	11	No treatment	−(0)	71	54 to >100

^*Number of mice analyzed. At 4 weeks, six animals receiving 0.25 × 10⁶ of LCL 12AI and simvastatin, six animals receiving 1 × 10⁶ of 12A1 and simvastatin, and two animals receiving 4 × 10⁶ 12A1 and simvastatin died or were sacrificed because of simvastatin side effects. These included severe weight loss, hunched body, or red swollen eyes. Autopsies showed no evidence of ascites or lymphomas in these mice and they were not included in the table and were excluded from the analysis.

^†Time of therapy. Animals received simvastatin 3 days before (pretreatment) or 7 days after (treatment) inoculation with LCLs.

^‡Significance. P values indicated are for mice treated with simvastatin versus mice not treated with the drug for each cell number.